The use of psychoactive drugs without medical supervision is associated with significant health risks and can lead to the development of drug use disorders. Drug use disorders, particularly when untreated, increase morbidity and mortality risks for individuals, can trigger substantial suffering and lead to impairment in personal, family, social, educational, occupational or other important ...
The Unit works globally to improve health and well-being of populations by articulating, promoting, supporting and monitoring evidence-informed policies, strategies and interventions to reduce the burden associated with alcohol, drugs and addictive behaviours.
Mena FN: Heart Failure Clinical Trial Pipeline Accelerates As 70+ Pharma Companies Rigorously Develop Drugs For Market Entry Delveinsight
DelveInsight's,“ Heart Failure Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Heart Failure pipeline landscape. It covers the Heart Failure ...
Heart Failure Clinical Trial Pipeline Accelerates As 70+ Pharma Companies Rigorously Develop Drugs For Market Entry Delveinsight
About WHO Drug Information WHO Drug Information is a quarterly journal providing an overview of topics relating to medicines development and regulation which is targeted to a wide audience of health professionals and policy makers. Launched in 1987, WHO Drug Information communicates the latest international news and trends to regulatory agencies, academic and training institutions, researchers ...
Publications of the World Health Organization Home / Publications / Overview / Canada: A List of Essential Prescription Drugs and Related Products-Initial Recommendation 2025 (English)
This report presents the first World Health Organization (WHO) analysis of antifungal agents in preclinical and clinical development. It covers systemic antifungal drugs in development worldwide, including label extension and repurposed products, and critically evaluates how well the current pipeline addresses infections caused by WHO fungal priority pathogens.